Insulet Corporation
Insulet Corporation Announces Medical Device Correction
Summary
On April 29, 2026, Insulet Corporation reported a voluntary Medical Device Correction involving 476 serious injuries and no deaths, as confirmed by the U.S. Food and Drug Administration (FDA). This update follows the company's initial report on March 12, 2026, which included 18 serious adverse events. The latest communication from the FDA on April 29, 2026, indicates that the number of reported serious injuries has increased to 476, with no deaths. The company has also added 13 expired lots to the correction, which does not impact the previously communicated financial impact.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement